Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Jason R. Myers

dblp:65/10932 · DBLP profile ↗
← Back
1ranked-venue papers
0as first author
0since 2021 · last 2012
—ORCID · unresolved

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 100%

Topics — the 2 heaviest of 3, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology
next-generation sequencing
0.112012
ART: a next-generation sequencing read simulator · Bioinform. 2012
Bioinformatics and computational biology
sequencing simulation
0.112012
ART: a next-generation sequencing read simulator · Bioinform. 2012

Methods — techniques the papers use, named apart from their topics

read error model · 0.1quality profile · 0.1
YearPublicationVenuePosition
2012 ART: a next-generation sequencing read simulator
abstract
UNLABELLED: ART is a set of simulation tools that generate synthetic next-generation sequencing reads. This functionality is essential for testing and benchmarking tools for next-generation sequencing data analysis including read alignment, de novo assembly and genetic variation discovery. ART generates simulated sequencing reads by emulating the sequencing process with built-in, technology-specific read error models and base quality value profiles parameterized empirically in large sequencing datasets. We currently support all three major commercial next-generation sequencing platforms: Roche's 454, Illumina's Solexa and Applied Biosystems' SOLiD. ART also allows the flexibility to use customized read error model parameters and quality profiles. AVAILABILITY: Both source and binary software packages are available at http://www.niehs.nih.gov/research/resources/software/art.
Weichun Huang, Leping Li, Jason R. Myers, Gabor T. Marth
Bioinform.3